ArticleBMC pulmonary medicine2025
Retrospective study on transfusion-related acute lung injury after intraoperative and postoperative blood transfusion in patients at a single medical center.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionTransfusion-related acute lung injury (TRALI) is a life-threatening syndrome that occurs within six hours of a blood transfusion. MATERIALS AND
methodsThe objective of this study was to investigate the characteristics, clinical manifestations, outcomes, and risk factors of TRALI in patients who underwent surgery at a single medical centre of China. The retrospective study included 5,846 patients who received intraoperative and postoperative blood transfusions. All donors implicated in TRALI cases were tested for anti-HLA class I and II antibodies using LABScreen Multi assay and for granulocyte antibodies using granulocyte agglutination test.
resultsFour patients (4/5846, 0.068%) developed TRALI, with specific incidence of 0.26/100,000 blood product; 9/10,000 units of packed red blood cells (PRBC) (1/1,065); 16/10,000 units of fresh frozen plasma (FFP) (1/645); and 5/10,000 units of Apheresis platelets (AP)(1/2,120). In one patient, TRALI was found to be secondary to a human leukocyte antigen (HLA) class I antibody (anti-HLA-A*11); in another, it was secondary to an HLA class II antibody (anti-HLA-DRB*04). The one with possibility of reverse TRALI was identified as a result of anti-A*24. One of the four patients was non-immunologically mediated TRALI.
conclusionsTo reduce the incidence and prevent TRALI, it is recommended that male donors and female donors who have never been pregnant or have tested negative for HLA antibodies since their last pregnancy should be selected for blood donation as much as possible. In addition, it is important to initiate clinical intervention and treatment at an early stage in order to improve the patient's prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.